Skip to content
10-K

Annual Report

Theriva Biologics, Inc. TOVX

0001104659-26-026767

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 45.89M sh
Shares Diluted FY 2025 · Dec 31, 2025 12.14M sh
Shares Diluted FY 2025 · Dec 31, 2024 1.35M sh
Capex FY 2025 · Dec 31, 2025 $35K
Capex FY 2025 · Dec 31, 2024 $1K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$16.67M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$16.94M
Long Term Debt FY 2025 · Dec 31, 2025 $1.67M
Long Term Debt FY 2025 · Dec 31, 2024 $92K
Cash And Equivalents FY 2025 · Dec 31, 2025 $13.06M
Cash And Equivalents FY 2025 · Dec 31, 2024 $11.61M
Current Liabilities FY 2025 · Dec 31, 2025 $10.01M
Current Liabilities FY 2025 · Dec 31, 2024 $7.59M
Total Liabilities FY 2025 · Dec 31, 2025 $22.86M
Total Liabilities FY 2025 · Dec 31, 2024 $16.29M
Current Assets FY 2025 · Dec 31, 2025 $17.47M
Current Assets FY 2025 · Dec 31, 2024 $16.28M
Total Assets FY 2025 · Dec 31, 2025 $38.24M
Total Assets FY 2025 · Dec 31, 2024 $35.35M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.08
Eps Diluted FY 2025 · Dec 31, 2024 −$19.03
Eps Basic FY 2025 · Dec 31, 2025 −$2.08
Eps Basic FY 2025 · Dec 31, 2024 −$19.03
Sga Expense FY 2025 · Dec 31, 2025 $15.45M
Sga Expense FY 2025 · Dec 31, 2024 $7.4M
Rd Expense FY 2025 · Dec 31, 2025 $8.6M
Rd Expense FY 2025 · Dec 31, 2024 $12.03M
Operating Income FY 2025 · Dec 31, 2025 −$24.05M
Operating Income FY 2025 · Dec 31, 2024 −$26.35M